Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

NCT01579578 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Stopped AstraZeneca sponsored trials of AZD8931 have been halted

Conditions

Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Interventions

DRUG: AZD8931
DRUG: Placebo
DRUG: Paclitaxel

Sponsor

AstraZeneca